Failure of a Pure Anti-Platelet Drug to Decrease the Number of Attacks More Than Placebo in Patients With Raynaud's Phenomenon

Destors, J. M.; Gauthier, E.; Lelong, S.; Boissel, J. P.
August 1986
Angiology;Aug1986, Vol. 37 Issue 8, p565
Academic Journal
Fifty-eight patients with Raynaud's phenomenon were randomly allocated in a six week double-blind clinical trial in parallel groups to compare the efficacy of a pure antiplatelet agent, ticlopidine (250 mg b.i.d.) with that of a placebo. There was no significant difference between the two treatments in percent reduction of weekly number of attacks and in subjective improvement assessed by both patient and investigator. It is unlikely that platelets are involved in the mechanisms of Raynaud's crisis.


Related Articles

  • Nicardipine in the Treatment of Raynaud's Phenomenon: A Randomized Double-Blind Trial. Kahan, André; Amor, Bernard; Menkès, Charles J.; Weber, Simon; Guérin, Francois; Degeorges, Michel // Angiology;Apr1987, Vol. 38 Issue 4, p333 

    The efficacy of the calcium-channel blocker nicardipine in the treatment of Raynaud's phenomenon was assessed in a prospective, double-blind, randomized, crossover trial in 20 patients. Each patient received nicardipine 20 mg or placebo three times a day for two weeks and then was crossed over...

  • Alpha and Beta-Blockade and Beta-Stimulation in Raynaud's Syndrome: A Double-Blind, Placebo Controlled, Single Dose Study. Cleophas, Ton J. M.; Fennis, Jan F. M.; van 't Laar, Albert // Angiology;Apr1985, Vol. 36 Issue 4, p219 

    We examined in a double blind fashion and placebo controlled the effects of some alpha and beta adrenergic receptor agonists and antagonists on the recovery of finger skin temperature 12 mm after finger cooling (5 mm waterbath for both hands) in twelve patients with Raynaud's syndrome. A...


    The article focuses on the experimentally controlled evaluation of vasoactive drugs in digital ischemia. The objective assessment of any allegedly vasoactive drug must be based upon methods which demonstrate clearly whether or not it can abolish or diminish the effect of vasoconstrictor stimuli,...

  • Treatment of Raynaud's Syndrome with Adrenergic Alpha-Blockade with or without Beta-Blockade. Cleophas, Ton J. M.; van Lier, Henk J. J.; Fennis, Jan F. M.; van 't Laar, Albert // Angiology;Jan1984, Vol. 35 Issue 1, p29 

    In a double blind placebo-controlled cross-over trial of 24 weeks 31 patients with Raynaud's syndrome were treated with the alpha-blocker phenoxybenzamine (10–20 mg daily) and with the combination of the alpha-blocker phenoxybenzamine (10–20 mg daily) and the beta-blocker sotalol...

  • Cold as Ice. Cimons, Marlene // Runner's World;Dec2000, Vol. 35 Issue 12, p46 

    Presents information on Raynaud's disease.

  • Dose-response patterns for vibration-induced white finger. Griffin, M.J.; Bovenzi, M.; Nelson, C.M. // Occupational & Environmental Medicine;Jan2003, Vol. 60 Issue 1, p16 

    Presents a study that investigated alternative relations between cumulative exposures to hand-transmitted vibration with the development of white finger or Raynaud's phenomenon. Factor associated with an increase in dose for all alternative dose measures; Way of predicting the occurrence of...

  • Beneficial Effects of Intermittent Suction and Pressure Treatment in Intermittent Claudication. Mehlsen, Jesper; Himmelstrup, Holger; Himmelstrup, Bodil; Winther, Kaj; Trap-Jensen, Jens // Angiology;Jan1993 Supplement, Vol. 44, p16 

    The present study reports on the effects of a physical treatment modality in patients with intermittent claudication. During this treatment a major part of the skin surface is subjected to intermittent suction and pressure. In a previous, preliminary study the authors found a beneficial effect...

  • A New 'TRIST?' Subset Data Keeping TroVax Hopes Alive. Boggs, Jennifer // BioWorld Today;9/23/2009, Vol. 20 Issue 183, p1 

    The article analyzes the results of the 733-patient TroVax Renal Immunotherapy Survival trial (TRIST) study in Phase III renal cancer trial of Oxford BioMedica presented at the European oncology conference. The report demonstrated no significant survival advantage in the treated group over...

  • Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials. Shaddinger, Bonnie C.; Xu, Yanmei; Roger, James H.; Macphee, Colin H.; Handel, Malcolm; Baidoo, Charlotte A.; Magee, Mindy; Lepore, John J.; Sprecher, Dennis L. // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: We explored the theorized upregulation of platelet-activating factor (PAF)– mediated biologic responses following lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibition using human platelet aggregation studies in an in vitro experiment and in 2 clinical trials. Methods...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics